Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Consensus Rating of "Moderate Buy" by Analysts
Ironwood Pharmaceuticals (NASDAQ:IRWD) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $3.68. Several brokerages, including Wells Fargo and Citizens JMP, recently upgraded their ratings and raised price targets. The company beat Q3 earnings and revenue expectations, and institutional buying has significantly increased, indicating strong investor confidence despite recent stock fluctuations.
Universal Beteiligungs und Servicegesellschaft mbH Lowers Stock Holdings in Ironwood Pharmaceuticals, Inc. $IRWD
Universal Beteiligungs und Servicegesellschaft mbH significantly reduced its stake in Ironwood Pharmaceuticals (NASDAQ:IRWD) by 76.3% in the third quarter of 2025, selling 401,900 shares and retaining 124,875 shares valued at $164,000. Despite this, analyst sentiment remains largely positive, with several firms upgrading IRWD to "strong-buy" or "outperform," resulting in a consensus "Moderate Buy" rating and an average target price of $3.68. Ironwood Pharmaceuticals recently reported stronger-than-expected earnings for the quarter, with an EPS of $0.24 against a $0.09 consensus and revenue of $122.06 million, surpassing expectations of $74.22 million.
Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) Fits the Minervini High-Growth Momentum Trend Template
Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) is presented as a strong candidate fitting Mark Minervini's "Trend Template" and "High Growth Momentum" criteria. The stock demonstrates technical strength with its price above key moving averages and high relative strength, coupled with robust fundamental growth including 1100% EPS growth and positive analyst revisions. Despite a high overall technical rating, the article notes a lower setup quality for immediate purchase, suggesting waiting for price stability.
Ironwood Pharmaceuticals (NASDAQ:IRWD) Trading Up 8.4% - Here's Why
Ironwood Pharmaceuticals (NASDAQ:IRWD) saw its shares jump 8.4% on Wednesday following a strong earnings report that beat analyst expectations for both EPS and revenue. The company also received several analyst upgrades and higher price targets, leading to a "Moderate Buy" consensus rating. Despite light trading volume, the positive sentiment reflects investor confidence in the company's recent performance and future outlook.
Ironwood Pharmaceuticals (IRWD) price target increased by 94.00% to 4.95
This article reports that the price target for Ironwood Pharmaceuticals (IRWD) has been increased by 94.00%, raising it to $4.95. No other details are provided in the current content.
This drugmaker cut a list price — and still expects higher 2026 sales
Ironwood Pharmaceuticals (IRWD) announced its financial guidance for full-year 2026, expecting LINZESS U.S. net sales of $1.125 to $1.175 billion and adjusted EBITDA greater than $300 million, despite lowering the LINZESS list price. The company maintains its 2025 financial guidance and plans to initiate a confirmatory Phase 3 trial for apraglutide in early 2026 for short bowel syndrome. The anticipated increase in net sales for LINZESS in 2026 is attributed to the elimination of the inflationary component of statutory rebates following the price decrease.
Ironwood Pharmaceuticals’ 2026 Guidance Shock Sparks a Major Re-Rating
Ironwood Pharmaceuticals saw its stock rally significantly after releasing 2026 financial guidance that far exceeded analyst expectations, projecting revenues 40% higher than anticipated. This unexpected performance was driven by a strategic decision to cut the list price of its drug LINZESS, which eliminated large rebate penalties and improved net revenue. The increased cash flow will also fully fund the upcoming Phase 3 trials for its pipeline asset apraglutide, removing a key area of investor uncertainty.
Why Ironwood Pharmaceuticals (IRWD) Is Up 37.8% After New 2026 Guidance And Ferring Settlement
Ironwood Pharmaceuticals (IRWD) saw its stock rise 37.8% following the maintenance of its 2025 earnings guidance, new 2026 revenue guidance of US$450 to US$475 million, and a settlement with Ferring regarding a license agreement. The settlement resolves legal uncertainties around VectivBio's licensed products, simplifying commercialization. The article suggests that while the new guidance supports the long-term investment narrative, ongoing regulatory progress for apraglutide and risks related to LINZESS reimbursement and debt obligations remain key factors for investors.
Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Shares Bounce 32% But Its Business Still Trails The Industry
Ironwood Pharmaceuticals (NASDAQ:IRWD) shares have recently risen 32%, but its price-to-sales (P/S) ratio of 2.2x is significantly lower than the industry average, indicating potential concerns about its business prospects. The company's revenue has declined by 10% in the last year and 19% over three years. Analysts forecast future revenue growth of 12% per year, which is considerably less than the industry's projected 123% annual expansion, explaining the low P/S ratio.
Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance
Ironwood Pharmaceuticals (Nasdaq: IRWD) announced its financial guidance for full year 2026, targeting LINZESS U.S. net sales of $1.125 to $1.175 billion, total revenues of $450 to $475 million, and adjusted EBITDA exceeding $300 million. The company is maintaining its FY 2025 financial guidance and ended Q4 2025 with over $200 million in cash. Ironwood also plans to initiate a confirmatory Phase 3 trial for apraglutide in the first half of 2026.
Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance
Ironwood Pharmaceuticals (Nasdaq: IRWD) has reaffirmed its financial guidance for FY 2025 and introduced its guidance for FY 2026, projecting LINZESS® U.S. net sales of $1.125 to $1.175 billion and total revenues of $450 to $475 million for 2026. The company anticipates adjusted EBITDA of over $300 million for 2026 and closed Q4 2025 with more than $200 million in cash. Ironwood also plans to initiate a confirmatory Phase 3 trial for apraglutide in short bowel syndrome with intestinal failure (SBS-IF) in the first half of 2026.
Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance
Ironwood Pharmaceuticals announced its financial guidance for full year 2026, while maintaining its previously issued FY 2025 guidance. The company expects full-year 2026 LINZESS U.S. net sales of $1.125 to $1.175 billion, total revenues of $450 to $475 million, and adjusted EBITDA of greater than $300 million. Ironwood also reported ending Q4 2025 with over $200 million in cash and cash equivalents and is on track to initiate a confirmatory Phase 3 trial for apraglutide in the first half of 2026.
Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) announced its financial guidance for full-year 2026, expecting LINZESS U.S. net sales of $1.125 to $1.175 billion, total revenues of $450 to $475 million, and adjusted EBITDA greater than $300 million. The company also confirmed it ended Q4 2025 with over $200 million in cash and cash equivalents and is on track to initiate a confirmatory Phase 3 trial for apraglutide in H1 2026. Ironwood is maintaining its FY 2025 guidance and attributes the anticipated increase in LINZESS net sales for 2026 to a lowered list price and the elimination of inflationary rebates.
Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance
Ironwood Pharmaceuticals (Nasdaq: IRWD) has maintained its financial guidance for FY 2025 and announced its guidance for FY 2026, projecting LINZESS U.S. net sales of $1.125 to $1.175 billion, total revenues of $450 to $475 million, and adjusted EBITDA exceeding $300 million for 2026. The company ended Q4 2025 with over $200 million in cash and cash equivalents and is on track to initiate a confirmatory Phase 3 trial for apraglutide in the first half of 2026. Ironwood attributes anticipated increased LINZESS net sales in 2026 to a lowered list price effective January 1, 2026, helping eliminate the inflationary component of statutory required rebates.
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives Average Recommendation of "Hold" from Brokerages
Ironwood Pharmaceuticals (NASDAQ:IRWD) has received an average "Hold" recommendation from eight brokerages, with a mean 12-month price target of $5.34. The company recently reported strong quarterly earnings, significantly beating analyst expectations for both EPS and revenue. Institutional investors have been increasing their stakes in IRWD, while its shares trade around $3.54 with a market capitalization near $576 million.
Need To Know: Analysts Are Much More Bullish On Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Revenues
Analysts have significantly upgraded their revenue and earnings forecasts for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) for 2026, leading to a 68% increase in the price target to US$1.85. Despite the market optimism and recent stock price gains, the company's revenue is still projected to decline faster than the wider industry. The report suggests considering the long-term trajectory of earnings rather than just next year's forecasts.
Ironwood (IRWD) Skyrockets 23% as Govt Price for Linzess Falls Within Expectations
Ironwood Pharmaceuticals (IRWD) saw its stock rise over 23% after the U.S. Department of Health and Human Services set the maximum fair price (MFP) for its bowel treatment, Linzess, at $136, a price that aligns with the company's expectations. This new price, effective January 1, 2027, is part of the Inflation Reduction Act to make healthcare more affordable. The company also reported a significant increase in third-quarter net income by 1,013% and a 33.27% jump in revenues, driven by Linzess sales.
Ironwood Pharmaceuticals (IRWD) Price Target Increased by 89.47% to 1.84
The average one-year price target for Ironwood Pharmaceuticals (IRWD) has been increased by 89.47% to $1.84 per share, up from $0.97. Despite this increase from prior estimates, the new average target still represents a decrease of 41.53% from the latest closing price of $3.14 per share. Institutional ownership data shows 338 funds holding positions, with some major shareholders maintaining or increasing their stakes.
There's No Escaping Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Muted Revenues Despite A 39% Share Price Rise
Despite a recent 39% surge in stock price, Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) faces challenges with muted revenues, leading to a low price-to-sales (P/S) ratio of 1.1x compared to the biotech industry average. The company's revenue has decreased by 23% in the last year and 26% over three years, with analysts forecasting a further 14% annual decline for the next three years. This outlook suggests that the current P/S ratio reflects investor concerns about future growth, making a significant stock price increase unlikely without a material change in revenue performance.
Need To Know: Analysts Are Much More Bullish On Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Revenues
Analysts have significantly upgraded their revenue and earnings forecasts for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) for 2026, leading to a substantial increase in the share price. Despite these improvements, the company's revenue is still expected to decline, albeit less severely than previously projected, and at a faster rate than the industry average. The positive revisions have also led to an increased price target, suggesting growing optimism among analysts.
Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance
Ironwood Pharmaceuticals reported strong Q3 2025 results, with LINZESS U.S. net sales increasing 40% year-over-year to $315 million and GAAP net income reaching $40 million. The company raised its full-year 2025 financial guidance for LINZESS U.S. net sales, total revenue, and adjusted EBITDA, driven by accelerated prescription demand growth and improved net pricing. Ironwood also highlighted the FDA approval of LINZESS for IBS-C in children aged 7 and older and its progress on the apraglutide program.
Ironwood Pharmaceuticals (NASDAQ:IRWD investor three-year losses grow to 84% as the stock sheds US$36m this past week
Ironwood Pharmaceuticals (NASDAQ:IRWD) shareholders have experienced an 84% loss over the last three years, despite a 102% gain in the past three months. The company's EPS has also declined to a loss-making position during this period, correlating with the share price drop. While the broader market gained 16% in the last year, Ironwood Pharmaceuticals shareholders lost 65%, compounding a 13% annual loss over five years.
Inspire Investing LLC Raises Stock Holdings in Ironwood Pharmaceuticals, Inc. $IRWD - MarketBeat
Inspire Investing LLC significantly increased its stake in Ironwood Pharmaceuticals (NASDAQ:IRWD) by 138.3% in the second quarter, bringing its total holdings to 552,420 shares. Other institutional investors also raised their positions in the company, which saw its stock decline by 6.6% but reported strong quarterly earnings that exceeded expectations. Ironwood Pharmaceuticals, with a market capitalization of $240.40 million, focuses on developing and commercializing gastrointestinal products.
Ironwood Pharmaceuticals director Andrew Dreyfus to resign effective November 1
Andrew Dreyfus will resign from the Board of Directors of Ironwood Pharmaceuticals, Inc. effective November 1, 2025, due to his appointment as President and CEO of the National Institute for Health Care Management Foundation. The company, which recently changed its auditor from EY to KPMG, noted that his departure was not due to any disagreements. Ironwood Pharmaceuticals (NASDAQ:IRWD) has a market capitalization of $287.51 million.
Ironwood Pharmaceuticals (NASDAQ:IRWD) Rating Increased to Strong-Buy at Zacks Research
Zacks Research has upgraded Ironwood Pharmaceuticals (NASDAQ:IRWD) to a "strong-buy" rating due to increased confidence in the company's stock. This upgrade follows Ironwood Pharmaceuticals' strong financial performance, significantly surpassing analysts' earnings and revenue expectations. Institutional investors are also actively increasing their holdings in the company, indicating growing market interest.
These biotechs are in the market for a buyer
Several Boston-area biotechs are actively seeking "strategic alternatives," such as acquisitions or asset sales, in 2025. Ironwood Pharmaceuticals Inc., for instance, has engaged Goldman Sachs & Co. LLC to explore potential deals. The article suggests that these companies are still on the lookout for buyers or collaborators.
Keep An Eye On Ironwood Pharmaceuticals As Insider Stock Selling Hits US$515k
Insiders at Ironwood Pharmaceuticals (NASDAQ:IRWD) have sold US$515k worth of stock over the past year, primarily at an average price higher than the current market value, suggesting they might be in a better position than if they had held. While overall insider selling has been observed, the recent sales over the last three months were minor at US$11k, and the company's insiders still own 2.4% of the shares, valued at US$4.0m. This article examines the recent insider transactions and their implications for the stock.
Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance
Ironwood Pharmaceuticals reported its second-quarter 2025 financial results, with LINZESS recording $248 million in U.S. net sales, marking a 17% increase year-over-year. The company confirmed its full-year 2025 financial guidance and plans to align with the FDA in Q4 2025 on the design for a confirmatory Phase 3 trial for apraglutide, targeting patients with short bowel syndrome. Ironwood is also actively reviewing strategic alternatives to enhance shareholder value for its two key assets.
Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance
Ironwood Pharmaceuticals (Nasdaq: IRWD) has reported its second quarter 2025 financial results, maintaining its full-year 2025 financial guidance. The company saw LINZESS® (linaclotide) U.S. net sales of $248 million in Q2 2025, with a 10% year-over-year EUTRx demand growth. Ironwood is also advancing apraglutide for short bowel syndrome and is progressing a strategic review to enhance shareholder value.
IRONWOOD PHARMACEUTICALS Earnings Results: $IRWD Reports Quarterly Earnings | IRWD Stock News
IRONWOOD PHARMACEUTICALS (IRWD) reported strong quarterly earnings, beating analyst estimates for both earnings per share and revenue. The article details recent insider trading activity, showing more sales than purchases, and provides an overview of hedge fund adjustments to their IRWD holdings. Additionally, it lists recent price targets from several analysts, with a median target of $1.0.
Ironwood Pharmaceuticals (IRWD) Beats Q2 Earnings and Revenue Estimates
Ironwood Pharmaceuticals (IRWD) reported Q2 earnings of $0.14 per share, significantly surpassing the Zacks Consensus Estimate of a $0.02 loss per share, following a previous quarter's negative surprise. The company also exceeded revenue estimates for the quarter, posting $85.24 million against a consensus of $61.84 million, despite a year-over-year decline from $94.4 million. While the stock has underperformed the S&P 500 year-to-date, its current Zacks Rank #3 (Hold) suggests it's expected to perform in line with the market in the near future.
Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance
Ironwood Pharmaceuticals has reiterated its full-year 2025 LINZESS U.S. net sales guidance of $800-$850 million and total revenue guidance of $260-$290 million. The company also raised its adjusted EBITDA guidance to greater than $105 million for 2025. This adjustment is due to discontinuing certain apraglutide commercial launch planning investments, shifting focus to its confirmatory Phase 3 trial.
Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance
Ironwood Pharmaceuticals reiterated its full-year 2025 LINZESS U.S. net sales and total revenue guidance while raising its adjusted EBITDA guidance to greater than $105 million for the year. The company reported continued strong LINZESS prescription demand growth of 8% year-over-year in Q1 2025, which was offset by anticipated pricing headwinds and a change in estimate for gross-to-net rebate reserves, though this is not expected to impact full-year results. The increased EBITDA guidance reflects a shift away from certain apraglutide commercial launch planning investments, focusing instead on a confirmatory Phase 3 trial.
IRWD Stock Price, News & Analysis
Ironwood Pharmaceuticals (IRWD) is a biotechnology company specializing in therapies for gastrointestinal and rare diseases, listed on the Nasdaq Global Select Market. Its main product is LINZESS, co-commercialized with AbbVie in the U.S. for IBS-C and CIC, and it is also developing apraglutide for short bowel syndrome. The company's revenue is largely tied to LINZESS sales and it has been exploring strategic alternatives to maximize shareholder value.
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call
Ironwood Pharmaceuticals, Inc. announced it will host its fourth quarter and full year 2024 investor update conference call and webcast on Thursday, February 27, 2025, at 8:30 a.m. Eastern Time. The company, which focuses on gastrointestinal and rare diseases, invites investors to participate via dial-in or webcast. A replay will be available for a limited time following the live event.
Ironwood Pharmaceuticals CEO Thomas A. McCourt sells $244,752 in stock By Investing.com
Thomas A. McCourt, CEO of Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), sold 139,064 shares totaling $244,752 to cover tax obligations. Despite the stock's significant decline, the company maintains strong liquidity, and analysts project a return to profitability this year, with a focus on apraglutide development. The company has also reduced its workforce and updated its financial guidance for 2025.
Ironwood Pharmaceuticals Reports Third Quarter 2024 Results
Ironwood Pharmaceuticals (NASDAQ: IRWD) announced its Q3 2024 results, highlighted by strong LINZESS prescription demand growth (13% year-over-year) despite pricing headwinds, allowing the company to maintain its full-year 2024 financial guidance. The company also confirmed it is on track to submit the apraglutide NDA in Q1 2025 for adult patients with short bowel syndrome, expecting it to be a preferred treatment. Financially, total revenue decreased to $91.6 million from $113.7 million in Q3 2023, and GAAP net income attributable to Ironwood was $3.6 million, down from $15.3 million in the prior year period.
Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call
Ironwood Pharmaceuticals (Nasdaq: IRWD) announced it will host its third quarter 2024 investor update conference call and webcast on Thursday, November 7, 2024, at 8:30 a.m. Eastern Time. The call will discuss company updates and financial performance, and replay information will be available for listeners unable to attend the live event. Ironwood Pharmaceuticals is a leading GI healthcare company known for LINZESS® and apraglutide, working to advance treatments for gastrointestinal diseases.
Investors in Ironwood Pharmaceuticals (NASDAQ:IRWD) from five years ago are still down 29%, even after 8.6% gain this past week
Investors in Ironwood Pharmaceuticals (NASDAQ:IRWD) who bought shares five years ago are still down 29%, despite an 8.6% gain this past week. The stock has also declined 20% over the last twelve months and 39% in the past quarter, indicating ongoing challenges for the company. Despite an increase in revenue, the company posted a loss in the last twelve months, suggesting further investigation into its fundamentals is needed.
Ironwood Pharmaceuticals CEO & Director Thomas McCourt Sells 39% Of Holding
Ironwood Pharmaceuticals' CEO & Director, Thomas McCourt, recently sold shares worth US$2.7 million at an average price of US$15.24, reducing his total holding by 39%. This was the largest insider sale for the company in the last year, occurring around the current share price of US$14.58. While the sale is a significant personal transaction, the article notes that insider ownership still stands at 1.8% (US$41 million), indicating some alignment with shareholders, but the overall insider selling trend suggests caution.
COUR Pharmaceuticals Secures $105 Million in Series A
COUR Pharmaceuticals has secured $105 million in Series A financing, co-led by Lumira Ventures and Alpha Wave Ventures, with participation from major pharmaceutical companies and investment funds. These funds will advance COUR's Myasthenia Gravis and Type 1 Diabetes product candidates into Phase 2a clinical trials and support other pipeline opportunities. The investment highlights confidence in COUR's proprietary antigen-specific immune tolerance platform for treating autoimmune and inflammatory diseases.
June 12 Quick Takes: AZ’s first-in-class AKT inhibitor under review
AstraZeneca's first-in-class AKT inhibitor, capivasertib, combined with fulvestrant, is under priority review by the FDA for HR-positive, HER2-negative breast cancers, with a PDUFA date set for Q4. The submission is supported by Phase III CAPItello-291 study data showing significant progression-free survival. Additionally, Simcere Pharmaceutical Group has expanded its presence in Massachusetts through a sponsored research agreement with Mass General Brigham and established a new subsidiary focused on cancer therapies.
Ironwood Pharmaceuticals, inc (IRWD) Q3 2021 Earnings Call Transcript
Ironwood Pharmaceuticals (IRWD) discussed its Q3 2021 earnings, highlighting strong LINZESS prescription demand growth of 12% year-over-year. The company announced an option agreement with COUR Pharmaceuticals for CNP-104, a potential disease-modifying therapy for primary biliary cholangitis (PBC), expanding its GI pipeline. Ironwood also reaffirmed its 2021 financial guidance, expecting U.S. net sales growth for LINZESS between 6% to 8% and adjusted EBITDA greater than $210 million.
AstraZeneca amends collaboration with Ironwood for Linzess in China
AstraZeneca has amended its collaboration agreement with Ironwood Pharmaceuticals for Linzess in China, giving AstraZeneca sole responsibility for development, manufacturing, and commercialization of the drug in the region. Linzess, a treatment for irritable bowel syndrome with constipation (IBS-C), was approved in China in January 2019 and is expected to launch the same year. This new agreement aims to more efficiently bring the innovative medicine to patients, with AstraZeneca paying Ironwood $35 million in non-contingent payments and up to $90 million in sales-contingent milestone payments, plus ongoing royalties.
Ironwood Pharmaceuticals Announces Chief Executive Officers to Lead Ironwood and Cyclerion, Effective Upon Upcoming Separation
Ironwood Pharmaceuticals announced the appointment of new CEOs for both Ironwood and Cyclerion, effective upon the planned separation in the first half of 2019. Mark Mallon will become CEO of Ironwood, a gastrointestinal healthcare company, while Peter Hecht, current CEO and co-founder, will lead Cyclerion Therapeutics. This leadership change is intended to maximize the value of each business post-separation.
IRWD Stock Price and Chart — NASDAQ:IRWD
This page provides an overview of Ironwood Pharmaceuticals, Inc. (IRWD) stock, including its current price, market performance across various periods, key financial stats, and company information. It also features analyst ratings, ideas, technical analysis, and upcoming earnings dates. The article highlights recent stock movements, market capitalization, and details about its healthcare sector focus.
U.S. Food and Drug Administration Approves 72 mcg Dose of LINZESS® (linaclotide) for Adults with Chronic Idiopathic Constipation
The FDA has approved a new 72 mcg dose of LINZESS (linaclotide) for the treatment of chronic idiopathic constipation (CIC) in adult patients, providing physicians with more dosing flexibility. This new dose is expected to be available in the first quarter of 2017, complementing the existing 145 mcg dose for CIC and 290 mcg dose for IBS-C. The approval is based on a Phase III clinical trial demonstrating statistically significant improvement in bowel movements compared to placebo.
